IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $751.00.

A number of research firms recently commented on IDXX. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th.

Institutional Investors Weigh In On IDEXX Laboratories

A number of large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the period. Harbour Investments Inc. raised its holdings in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after acquiring an additional 16 shares during the period. CWA Asset Management Group LLC raised its holdings in shares of IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares during the period. Stratos Wealth Partners LTD. raised its holdings in shares of IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after acquiring an additional 18 shares during the period. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in shares of IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after acquiring an additional 18 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.5%

NASDAQ IDXX opened at $562.16 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company’s 50 day simple moving average is $563.05 and its 200 day simple moving average is $632.14. IDEXX Laboratories has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a market capitalization of $44.34 billion, a P/E ratio of 41.40, a PEG ratio of 3.08 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned $2.91 EPS. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.